Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 30

1.

A Phase 2 Study to Assess the Immunomodulatory Capacity of a Lecithin-based Delivery System of Curcumin in Endometrial Cancer.

Tuyaerts S, Rombauts K, Everaert T, Van Nuffel AMT, Amant F.

Front Nutr. 2019 Jan 11;5:138. doi: 10.3389/fnut.2018.00138. eCollection 2018.

2.

Endometrial Stromal Sarcomas: A Revision of Their Potential as Targets for Immunotherapy.

Tuyaerts S, Amant F.

Vaccines (Basel). 2018 Aug 25;6(3). pii: E56. doi: 10.3390/vaccines6030056. Review.

3.

Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer.

Tanyi JL, Bobisse S, Ophir E, Tuyaerts S, Roberti A, Genolet R, Baumgartner P, Stevenson BJ, Iseli C, Dangaj D, Czerniecki B, Semilietof A, Racle J, Michel A, Xenarios I, Chiang C, Monos DS, Torigian DA, Nisenbaum HL, Michielin O, June CH, Levine BL, Powell DJ Jr, Gfeller D, Mick R, Dafni U, Zoete V, Harari A, Coukos G, Kandalaft LE.

Sci Transl Med. 2018 Apr 11;10(436). pii: eaao5931. doi: 10.1126/scitranslmed.aao5931.

PMID:
29643231
4.

Acute Drug Effects on the Human Placental Tissue: The Development of a Placental Murine Xenograft Model.

Verheecke M, Hermans E, Tuyaerts S, Souche E, Van Bree R, Verbist G, Everaert T, Cortès-Calabuig A, Van Houdt J, Van Calsteren K, Amant F.

Reprod Sci. 2018 Dec;25(12):1637-1648. doi: 10.1177/1933719118756771. Epub 2018 Feb 13.

PMID:
29439620
5.

In Vitro Assessment of the Expression and T Cell Immunogenicity of the Tumor-Associated Antigens BORIS, MUC1, hTERT, MAGE-A3 and Sp17 in Uterine Cancer.

Vanderstraeten A, Tuyaerts S, Everaert T, Van Bree R, Verbist G, Luyten C, Amant F.

Int J Mol Sci. 2016 Sep 9;17(9). pii: E1525. doi: 10.3390/ijms17091525.

6.

mRNA Electroporation of Dendritic Cells with WT1, Survivin, and TriMix (a Mixture of caTLR4, CD40L, and CD70).

Coosemans A, Tuyaerts S, Morias K, Corthals J, Heirman C, Thielemans K, Van Gool SW, Vergote I, Amant F.

Methods Mol Biol. 2016;1428:277-83. doi: 10.1007/978-1-4939-3625-0_18.

PMID:
27236806
7.

Potential Therapeutic Targets in Uterine Sarcomas.

Cuppens T, Tuyaerts S, Amant F.

Sarcoma. 2015;2015:243298. doi: 10.1155/2015/243298. Epub 2015 Oct 21. Review.

8.

In Vitro Validation of Survivin as Target Tumor-associated Antigen for Immunotherapy in Uterine Cancer.

Vanderstraeten A, Everaert T, Van Bree R, Verbist G, Luyten C, Amant F, Tuyaerts S.

J Immunother. 2015 Jul-Aug;38(6):239-49. doi: 10.1097/CJI.0000000000000085.

PMID:
26049547
9.

Dendritic cell immunotherapy in uterine cancer.

Coosemans A, Tuyaerts S, Vanderstraeten A, Vergote I, Amant F, Van Gool SW.

Hum Vaccin Immunother. 2014;10(7):1822-7. doi: 10.4161/hv.28716.

10.

Variability in CRP, regulatory T cells and effector T cells over time in gynaecological cancer patients: a study of potential oscillatory behaviour and correlations.

Madondo MT, Tuyaerts S, Turnbull BB, Vanderstraeten A, Kohrt H, Narasimhan B, Amant F, Quinn M, Plebanski M.

J Transl Med. 2014 Jun 23;12:179. doi: 10.1186/1479-5876-12-179.

11.

Mapping the immunosuppressive environment in uterine tumors: implications for immunotherapy.

Vanderstraeten A, Luyten C, Verbist G, Tuyaerts S, Amant F.

Cancer Immunol Immunother. 2014 Jun;63(6):545-57.

12.

Wilms' Tumor Gene 1 (WT1)--loaded dendritic cell immunotherapy in patients with uterine tumors: a phase I/II clinical trial.

Coosemans A, Vanderstraeten A, Tuyaerts S, Verschuere T, Moerman P, Berneman ZN, Vergote I, Amant F, VAN Gool SW.

Anticancer Res. 2013 Dec;33(12):5495-500.

PMID:
24324087
13.

Immunological response after WT1 mRNA-loaded dendritic cell immunotherapy in ovarian carcinoma and carcinosarcoma.

Coosemans A, Vanderstraeten A, Tuyaerts S, Verschuere T, Moerman P, Berneman Z, Vergote I, Amant F, Van Gool SW.

Anticancer Res. 2013 Sep;33(9):3855-9.

PMID:
24023319
14.

Epitope and HLA-type independent monitoring of antigen-specific T-cells after treatment with dendritic cells presenting full-length tumor antigens.

Van Nuffel AM, Tuyaerts S, Benteyn D, Wilgenhof S, Corthals J, Heirman C, Neyns B, Thielemans K, Bonehill A.

J Immunol Methods. 2012 Mar 30;377(1-2):23-36. doi: 10.1016/j.jim.2011.12.010. Epub 2012 Jan 16.

PMID:
22269772
15.

Therapeutic vaccination with an autologous mRNA electroporated dendritic cell vaccine in patients with advanced melanoma.

Wilgenhof S, Van Nuffel AM, Corthals J, Heirman C, Tuyaerts S, Benteyn D, De Coninck A, Van Riet I, Verfaillie G, Vandeloo J, Bonehill A, Thielemans K, Neyns B.

J Immunother. 2011 Jun;34(5):448-56. doi: 10.1097/CJI.0b013e31821dcb31.

PMID:
21577140
16.

Dendritic cell therapy for oncology roundtable conference.

Tuyaerts S.

J Immune Based Ther Vaccines. 2011 Jan 12;9(1):1. doi: 10.1186/1476-8518-9-1.

17.

Single-step antigen loading and activation of dendritic cells by mRNA electroporation for the purpose of therapeutic vaccination in melanoma patients.

Bonehill A, Van Nuffel AM, Corthals J, Tuyaerts S, Heirman C, François V, Colau D, van der Bruggen P, Neyns B, Thielemans K.

Clin Cancer Res. 2009 May 15;15(10):3366-75. doi: 10.1158/1078-0432.CCR-08-2982. Epub 2009 May 5.

18.

Enhancing the T-cell stimulatory capacity of human dendritic cells by co-electroporation with CD40L, CD70 and constitutively active TLR4 encoding mRNA.

Bonehill A, Tuyaerts S, Van Nuffel AM, Heirman C, Bos TJ, Fostier K, Neyns B, Thielemans K.

Mol Ther. 2008 Jun;16(6):1170-80. doi: 10.1038/mt.2008.77. Epub 2008 Apr 22.

19.

Delivery of tumor-antigen-encoding mRNA into dendritic cells for vaccination.

Michiels A, Tuyaerts S, Bonehill A, Heirman C, Corthals J, Thielemans K.

Methods Mol Biol. 2008;423:155-63. doi: 10.1007/978-1-59745-194-9_10.

PMID:
18370196
20.

Current approaches in dendritic cell generation and future implications for cancer immunotherapy.

Tuyaerts S, Aerts JL, Corthals J, Neyns B, Heirman C, Breckpot K, Thielemans K, Bonehill A.

Cancer Immunol Immunother. 2007 Oct;56(10):1513-37. Epub 2007 May 15. Review.

PMID:
17503040

Supplemental Content

Loading ...
Support Center